Earlier this summer, Howard Lovy (Fierce Biomarkers) echoed the frustration of the medical community with the often over-hyped publicity surrounding reports of new biomarkers while true medical impact remains elusive (read the full post here).
I believe that bridging the gap between the early excitement of discovery and the true satisfaction of positively affecting patient health requires a new mindset focused on bringing to the biomarker field the same development processes used in drug development (see my earlier post: “Translational Biomarker Development: mind the gap”).
Thierry
Sornasse for Integrated Biomarker Strategy
No comments:
Post a Comment